Allogene Therapeutics (ALLO) Equity Average: 2019-2025
Historic Equity Average for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $329.9 million.
- Allogene Therapeutics' Equity Average fell 32.58% to $329.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.9 million, marking a year-over-year decrease of 32.58%. This contributed to the annual value of $467.2 million for FY2024, which is 20.75% down from last year.
- Per Allogene Therapeutics' latest filing, its Equity Average stood at $329.9 million for Q3 2025, which was down 9.60% from $365.0 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Equity Average ranged from a high of $1.1 billion in Q1 2021 and a low of $329.9 million during Q3 2025.
- For the 3-year period, Allogene Therapeutics' Equity Average averaged around $490.0 million, with its median value being $488.2 million (2024).
- As far as peak fluctuations go, Allogene Therapeutics' Equity Average spiked by 73.96% in 2021, and later crashed by 32.58% in 2025.
- Allogene Therapeutics' Equity Average (Quarterly) stood at $947.6 million in 2021, then decreased by 25.58% to $705.1 million in 2022, then dropped by 22.51% to $546.4 million in 2023, then fell by 18.94% to $443.0 million in 2024, then slumped by 32.58% to $329.9 million in 2025.
- Its last three reported values are $329.9 million in Q3 2025, $365.0 million for Q2 2025, and $403.8 million during Q1 2025.